Lymphoma Clinical Trials

Showing 401-420 of 1,633 trials

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

NCT04134325

LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).

Relapsed Hodgkin LymphomaRefractory Hodgkin Lymphoma

UNC Lineberger Comprehensive Cancer Center10 participantsStarted Sep 2019

Chapel Hill, North Carolina, United States

RECRUITINGPHASE1/PHASE2

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

NCT04494503

The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Ascentage Pharma Group Inc.123 participantsStarted Aug 2020

Beijing, Beijing Municipality, China • Chongqing, Chongqing Municipality, China • Guangzhou, Guangdong, China +15 more locations

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Related Searches

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

AGMT Austrian Lymphoma Registry

Assessing the Presence of CT-DNA in Lymphoma Associated HLH

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Obinutuzumab in Marginal Zone Lymphoma

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma

Whole Body MRI in Oncology

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma